St. Jude Medical (NYSE:STJ) today said it’s launching the 1st trial comparing optical coherence tomography device with intravascular ultrasound or angiography during stenting procedures. St. Paul, Minn.-based St. Jude said the 420-patient Ilumien III trial will compare treatment with its Optis Integrated and Ilumien Optis percutaneous coronary intervention optimization systems in treating patients with stable or unstable angina, silent ischemia or […]
Imaging
Lantheus prices IPO below range
Lantheus Medical Imaging said yesterday it priced its initial public offering at $6.00 per share, below its previously announced range, for total proceeds of $65 million. The company is offering 10.8 million shares, with an underwriters over-allotment option of another 1.4 million, the North Billerica, Mass.-based company said. Credit Suisse Securities, Jefferies, RBC Capital Markets and […]
Biosense Webster launches cardiac mapping system
Johnson & Johnson (NYSE:JNJ) subsidiary Biosense Webster said last Thursday that it launched the Carto 3 system Confidense 3D cardiac mapping module for use during catheter ablation procedures. The module uses a proprietary algorithm to speed up the process of multi-electrode cardiac mapping, the company said, streamlining a validation process that previously had to be done manually. […]
Philips launches HeartModel intelligent ultrasound
Royal Philips (NYSE:PHG) said last week that it launched HeartModel A.I., an “anatomically intelligent” cardiac ultrasound with 3D echocardiogram capabilities. The announcement was made during the American Society of Echocardiography’s annual meeting in Boston. The HeartModel is 3 to 6 times faster than conventional 2D exams in gathering left ventricular and atrial dimensions and volumes, Philips said. The […]
Lantheus Medical sets terms for revived $75m IPO
Lantheus Medical Imaging set the terms for a revived initial public offering that would bring in nearly $75 million at the mid-point. North Billerica, Mass.-based Lantheus, which makes imaging agents and other diagnostic products, deals primarily in radiopharmaceutical and contrast agents. Last year the company said it planned to price the offering at $12 to $15 per share, […]
Augmenix touts publication of pivotal SpaceOar study
Augmenix said last week that a pivotal study of its SpaceOar system was published online in the International Journal of Radiation Oncology•Biology•Physics. The 222-patient pivotal study was designed to evaluate safety and efficacy of the SpaceOar System in men undergoing prostate radiotherapy, the company said. The SpaceOar is designed to separate the prostate from the rectal wall during radiation […]
PAD: Philips teams up with Dutch center on new diabetic foot imaging
Varian books $87m order on Maryland proton therapy center
FDA approves Siemens 3D breast tomo device
Siemens Healthcare (NYSE:SI) today said the FDA approved a new breast tomosynthesis option for its Mammomat Inspiration digital mammography device.
New mammography guidelines stick with screening from age 50
ViewRay rescinds $52m IPO
ViewRay yesterday became the latest medical device company to scrap an initial public offering, withdrawing a flotation that would have raised $52 million for its MRI-guided radiation therapy technology.